Abstract
Chromogranin A (CgA), a major component of the chromaffin granules, is co-stored and co-released with catecholamines. It is also expressed in extra-adrenal sites, including the heart. In the rat, CgA localizes in atrial myoendocrine cells, associated with Atrial Natriuretic Peptide (ANP), and in the conduction system. In the human heart it is present in the ventricular myocardium, co-localized with B-type NP (BNP). CgA is the precursor of several biologically active peptides generated by proteolytic processing also in the heart. Two of them, vasostatin-1 (VS-1) and catestatin (Cst), inhibit cardiac contraction and relaxation, counter-regulate beta-adrenergic and endothelinergic stimulation, and protect the heart against ischemia/reperfusion damages. Recently, clinical studies have suggested CgA to be involved also in cardiovascular pathologies. High plasma CgA levels were found in hypertension, chronic and acute heart failure, myocardial infarction, decompensated and hypertrophic heart, and acute coronary syndromes. These alterations correlate with those of conventional cardiovascular biomarkers, such as NP and endothelin-1 (ET-1), and have prognostic relevance, being indicative of both severity of the disease and mortality. Accordingly, the current knowledge indicates CgA as a multifaceted peptide in cardiovascular homeostasis. Whether the influence elicited by the protein on both normal and failing heart is beneficial and/or detrimental, as well as its implication in the cardiac neuroendocrine scenario is under intense investigation. This review will focus on: i) the involvement of CgA and its derived peptides in the mechanisms which sustain cardiac function and compensation, ii) CgA clinical relevance, and iii) its putative value as a clinical biomarker.
Keywords: Chromogranin-A, Heart, Heart failure, Myocardial infarction, Acute coronary syndromes, hromaffin granules, catecholamines, Natriuretic Peptide, ventricular myocardium, beta-adrenergic.
Current Medicinal Chemistry
Title:Chromogranin-A: A Multifaceted Cardiovascular Role in Health and Disease
Volume: 19 Issue: 24
Author(s): T. Angelone, R. Mazza and M. C. Cerra
Affiliation:
Keywords: Chromogranin-A, Heart, Heart failure, Myocardial infarction, Acute coronary syndromes, hromaffin granules, catecholamines, Natriuretic Peptide, ventricular myocardium, beta-adrenergic.
Abstract: Chromogranin A (CgA), a major component of the chromaffin granules, is co-stored and co-released with catecholamines. It is also expressed in extra-adrenal sites, including the heart. In the rat, CgA localizes in atrial myoendocrine cells, associated with Atrial Natriuretic Peptide (ANP), and in the conduction system. In the human heart it is present in the ventricular myocardium, co-localized with B-type NP (BNP). CgA is the precursor of several biologically active peptides generated by proteolytic processing also in the heart. Two of them, vasostatin-1 (VS-1) and catestatin (Cst), inhibit cardiac contraction and relaxation, counter-regulate beta-adrenergic and endothelinergic stimulation, and protect the heart against ischemia/reperfusion damages. Recently, clinical studies have suggested CgA to be involved also in cardiovascular pathologies. High plasma CgA levels were found in hypertension, chronic and acute heart failure, myocardial infarction, decompensated and hypertrophic heart, and acute coronary syndromes. These alterations correlate with those of conventional cardiovascular biomarkers, such as NP and endothelin-1 (ET-1), and have prognostic relevance, being indicative of both severity of the disease and mortality. Accordingly, the current knowledge indicates CgA as a multifaceted peptide in cardiovascular homeostasis. Whether the influence elicited by the protein on both normal and failing heart is beneficial and/or detrimental, as well as its implication in the cardiac neuroendocrine scenario is under intense investigation. This review will focus on: i) the involvement of CgA and its derived peptides in the mechanisms which sustain cardiac function and compensation, ii) CgA clinical relevance, and iii) its putative value as a clinical biomarker.
Export Options
About this article
Cite this article as:
Angelone T., Mazza R. and C. Cerra M., Chromogranin-A: A Multifaceted Cardiovascular Role in Health and Disease, Current Medicinal Chemistry 2012; 19 (24) . https://dx.doi.org/10.2174/092986712802430009
DOI https://dx.doi.org/10.2174/092986712802430009 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Epidemiological Characteristics of 64 Covid-19 Patients in Errachidia Province (Darâa-Tafilalet region), Morocco: A Retrospective Analysis
Reviews on Recent Clinical Trials The Emerging Role of Bradykinin in the Pathogenesis of Osteoarthritis and its Possible Clinical Implications
Current Rheumatology Reviews Early Timing of Endovascular Treatment for Aneurysmal Subarachnoid Hemorrhage Achieves Improved Outcomes
Current Neurovascular Research Mechanistic Insights into Mode of Action of a Potent Natural Antagonist of Orexin Receptor-1 by Means of High Throughput Screening and Molecular Dynamics Simulations
Combinatorial Chemistry & High Throughput Screening Platelet Ca2+ATPases: Identification and Regulation in Hypertension
Current Hypertension Reviews Vitamin D Supplementation: A Promising Approach for the Prevention and Treatment of Strokes
Current Drug Targets Determination of Interchangeability of Different Brands of Diclofenac Sodium Sustained Release Tablets in Healthy Subjects Using Pharmacokinetic End Points
Letters in Drug Design & Discovery Drugs that Activate Specific Nitric Oxide Sensitive Guanylyl Cyclase Isoforms Independent of Nitric Oxide Release
Current Medicinal Chemistry Determinants of Human Coronary Collaterals
Current Cardiology Reviews The Role of Hyperglycaemia and the Hypercoagulable State in the Pathogenesis of Cardiovascular Events in Diabetes Mellitus: Implications for Hypertension Management
Current Pharmaceutical Design Clinical Herbal Interactions with Conventional Drugs: From Molecules to Maladies
Current Medicinal Chemistry Association of Oxidative Stress to the Genesis of Anxiety: Implications for Possible Therapeutic Interventions
Current Neuropharmacology The Economic Costs for the Control of Cardiovascular Risk: An Overview
Current Pharmaceutical Design Definitions of Metabolic Syndrome: Where are We Now?
Current Vascular Pharmacology Subject Index to Volume 3
Current Drug Targets - Cardiovascular & Hematological Disorders Combination of Daidzein, Hemin and Bms182874 Halts the Progression of Diabetes-Induced Experimental Nephropathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Resilient Brain Aging: Characterization of Discordance between Alzheimer’s Disease Pathology and Cognition
Current Alzheimer Research A Study of Metabolic Parameters in Patients with Gout: A Single Center Study from Nepal
Endocrine, Metabolic & Immune Disorders - Drug Targets The Use of Iontophoresis in the Administration of Nicotine and New Non-Nicotine Drugs through the Skin for Smoking Cessation
Current Drug Discovery Technologies Treat to Target in Spondyloarthritis: The Time has Come
Current Rheumatology Reviews